How to combine non-compartmental analysis with the population pharmacokinetics? A study of tobacco smoke's influence on the bioavailability of racemic citalopram in rats
- 1 March 2013
- journal article
- research article
- Published by Springer Nature in Pharmacological Reports
- Vol. 65 (2) , 517-524
Abstract
Background: Citalopram (CIT) is an antidepressant drug from the group ofselective serotonin reuptake inhibitors in which it is the most potent selective inhibitor ofserotonin uptake currently available. Patients treated with CIT are often heavy cigarette smokers. Individual pharmacokinetic parameters cannot be directly estimated if full pharmacokinetic profiles are not available for each subject. Sparse sampling is common to experiments using small animals, such as the case that our study is concerned with. Methods: The aim of the study was to demonstrate how the two (non-compartmental analysis (NCA) and nonlinear mixed-effect (NLME» approaches, used simultaneously, can help overcome specific limitations of these separate methods whilst at the same time preserve their respective benefits. Results: Despite the ultra-sparse design, the NLME approach enabled us to develop a pharmacostatistic model with the required covariate - exposition to the tobacco smoke. Conclusions: A tobacco smoke slows down the absorption of the CIT and at the same time makes it more effective. The consistency of results obtained both with NCA and NLME decreased the risk of model misspecification and increased confidence in the final conclusions. Combining NLME with NCA may therefore be recommended for investigating pharmacokinetic properties of the drug in the sparse designs.Keywords
This publication has 11 references indexed in Scilit:
- Bioequivalence Tests Based on Individual Estimates Using Non-compartmental or Model-Based Analyses: Evaluation of Estimates of Sample Means and Type I Error for Different DesignsPharmaceutical Research, 2009
- Effect of pregnancy and tobacco smoke on the antioxidant activity of rutin in an animal modelPharmacological Reports, 2009
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- Diagnosing Model DiagnosticsClinical Pharmacology & Therapeutics, 2007
- Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX SoftwareJournal of Pharmacokinetics and Pharmacodynamics, 2007
- The Population Pharmacokinetics of Citalopram After Deliberate Self-Poisoning: A Bayesian ApproachJournal of Pharmacokinetics and Pharmacodynamics, 2005
- Utility of Sparse Concentration Sampling for Citalopram in Elderly Clinical Trial SubjectsThe Journal of Clinical Pharmacology, 2004
- Pharmacokinetic comparison of oral solution and tablet formulations of citalopram: a single-dose, randomized, crossover studyClinical Therapeutics, 2000
- Variability of the Model-Independent AUC: The One Sample Per Individual CaseJournal of Pharmacokinetics and Biopharmaceutics, 1999
- Testing for the equality of area under the curves when using destructive measurement techniquesJournal of Pharmacokinetics and Biopharmaceutics, 1988